Using tetracyclines to treat osteoporotic/osteopenic bone loss

From the basic science laboratory to the clinic

Jeffrey B Payne, Lorne M. Golub

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Periodontitis (progressive inflammatory disease characterized by alveolar bone loss, a major cause of tooth loss worldwide) is associated with both systemic osteoporosis and its milder form, osteopenia. Tetracyclines, by virtue of their non-antimicrobial pro-anabolic and anti-catabolic properties, are excellent candidate pharmaceuticals to simultaneously treat these local and systemic disorders. This paper reviews the foundational basic science and translational research which lead to a pivotal multicenter randomized clinical trial in postmenopausal women with both periodontitis and systemic (skeletal) osteopenia. This trial was designed primarily to examine whether subantimicrobial dose doxycycline (SDD) could reduce progressive alveolar (oral) bone loss associated with periodontitis and, secondarily, whether SDD could reduce systemic bone loss in the same subjects. This paper describes the efficacy and safety findings from this clinical trial and also outlines future directions using this promising and novel approach to manage both oral and systemic bone loss.

Original languageEnglish (US)
Pages (from-to)121-129
Number of pages9
JournalPharmacological Research
Volume63
Issue number2
DOIs
StatePublished - Feb 1 2011

Fingerprint

Tetracyclines
Periodontitis
Alveolar Bone Loss
Doxycycline
Metabolic Bone Diseases
Bone and Bones
Tooth Loss
Translational Medical Research
Osteoporosis
Randomized Controlled Trials
Clinical Trials
Safety
Pharmaceutical Preparations

Keywords

  • Collagenases
  • Osteopenia
  • Osteoporosis
  • Periodontitis
  • Postmenopausal women
  • Subantimicrobial dose doxycycline

ASJC Scopus subject areas

  • Pharmacology

Cite this

Using tetracyclines to treat osteoporotic/osteopenic bone loss : From the basic science laboratory to the clinic. / Payne, Jeffrey B; Golub, Lorne M.

In: Pharmacological Research, Vol. 63, No. 2, 01.02.2011, p. 121-129.

Research output: Contribution to journalArticle

@article{eadfff55a84943609c1f9a6949e9ee11,
title = "Using tetracyclines to treat osteoporotic/osteopenic bone loss: From the basic science laboratory to the clinic",
abstract = "Periodontitis (progressive inflammatory disease characterized by alveolar bone loss, a major cause of tooth loss worldwide) is associated with both systemic osteoporosis and its milder form, osteopenia. Tetracyclines, by virtue of their non-antimicrobial pro-anabolic and anti-catabolic properties, are excellent candidate pharmaceuticals to simultaneously treat these local and systemic disorders. This paper reviews the foundational basic science and translational research which lead to a pivotal multicenter randomized clinical trial in postmenopausal women with both periodontitis and systemic (skeletal) osteopenia. This trial was designed primarily to examine whether subantimicrobial dose doxycycline (SDD) could reduce progressive alveolar (oral) bone loss associated with periodontitis and, secondarily, whether SDD could reduce systemic bone loss in the same subjects. This paper describes the efficacy and safety findings from this clinical trial and also outlines future directions using this promising and novel approach to manage both oral and systemic bone loss.",
keywords = "Collagenases, Osteopenia, Osteoporosis, Periodontitis, Postmenopausal women, Subantimicrobial dose doxycycline",
author = "Payne, {Jeffrey B} and Golub, {Lorne M.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1016/j.phrs.2010.10.006",
language = "English (US)",
volume = "63",
pages = "121--129",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Using tetracyclines to treat osteoporotic/osteopenic bone loss

T2 - From the basic science laboratory to the clinic

AU - Payne, Jeffrey B

AU - Golub, Lorne M.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Periodontitis (progressive inflammatory disease characterized by alveolar bone loss, a major cause of tooth loss worldwide) is associated with both systemic osteoporosis and its milder form, osteopenia. Tetracyclines, by virtue of their non-antimicrobial pro-anabolic and anti-catabolic properties, are excellent candidate pharmaceuticals to simultaneously treat these local and systemic disorders. This paper reviews the foundational basic science and translational research which lead to a pivotal multicenter randomized clinical trial in postmenopausal women with both periodontitis and systemic (skeletal) osteopenia. This trial was designed primarily to examine whether subantimicrobial dose doxycycline (SDD) could reduce progressive alveolar (oral) bone loss associated with periodontitis and, secondarily, whether SDD could reduce systemic bone loss in the same subjects. This paper describes the efficacy and safety findings from this clinical trial and also outlines future directions using this promising and novel approach to manage both oral and systemic bone loss.

AB - Periodontitis (progressive inflammatory disease characterized by alveolar bone loss, a major cause of tooth loss worldwide) is associated with both systemic osteoporosis and its milder form, osteopenia. Tetracyclines, by virtue of their non-antimicrobial pro-anabolic and anti-catabolic properties, are excellent candidate pharmaceuticals to simultaneously treat these local and systemic disorders. This paper reviews the foundational basic science and translational research which lead to a pivotal multicenter randomized clinical trial in postmenopausal women with both periodontitis and systemic (skeletal) osteopenia. This trial was designed primarily to examine whether subantimicrobial dose doxycycline (SDD) could reduce progressive alveolar (oral) bone loss associated with periodontitis and, secondarily, whether SDD could reduce systemic bone loss in the same subjects. This paper describes the efficacy and safety findings from this clinical trial and also outlines future directions using this promising and novel approach to manage both oral and systemic bone loss.

KW - Collagenases

KW - Osteopenia

KW - Osteoporosis

KW - Periodontitis

KW - Postmenopausal women

KW - Subantimicrobial dose doxycycline

UR - http://www.scopus.com/inward/record.url?scp=79251609692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251609692&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2010.10.006

DO - 10.1016/j.phrs.2010.10.006

M3 - Article

VL - 63

SP - 121

EP - 129

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 2

ER -